(A) Immunoblotting analysis to assess the knockdown efficiencies against TCF4 and LEF1. M000921 proliferative melanoma cells were treated with siCtrl, siTCF4, siLEF1, or siLEF1/siTCF4 in the absence or presence of 2 d of TGFβ, Wnt-3a, or siLATS1/2 stimulation. Immunoblotting for TCF4 and LEF1 validated the efficient knockdown of these proteins. GAPDH was used as loading control. (B) Quantitative RT-PCR analysis to assess knockdown efficiencies (TCF4, LEF1, LATS1, and LATS2) as well as Wnt target gene expression (AXIN1, NOTUM, NKD1, and CTLA4) expression upon Wnt-3a treatment or siLATS1/2 or TGFβ-induced phenotype switching in M000921 cells. (C) Quantitative RT-PCR analysis of melanocyte (MITF) and mesenchymal (FN1 and ZEB1) marker gene expression upon upon Wnt-3a treatment or siLATS1/2 or TGFβ-induced phenotype switching in M000921 cells. (D) Quantitative RT-PCR analysis of YAP/TAZ (CYR61 and CTGF) and YAP/TAZ/SMAD (SERPINE1 and ANKRD1) target gene expression upon siLATS1/2 or TGFβ-induced phenotype switching in M000921 cells. Mean + SEM of n = 3 replicates are shown. *P < 0.05; **P < 0.01; ***P < 0.005; ratio-paired t test. For clarity, bars without asterisks indicate statistically nonsignificant. Red asterisks indicate the respective comparisons to siCtrl. Black asterisks indicate the comparisons as highlighted by bars.